이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sorrento Therapeutics 관리

관리 기준 확인 3/4

Sorrento Therapeutics' CEO는 Henry Ji, Sep2012 에 임명되었습니다 의 임기는 11.33 년입니다. 총 연간 보상은 $ 10.07M, 20.1% 로 구성됩니다. 20.1% 급여 및 79.9% 보너스(회사 주식 및 옵션 포함). 는 $ 508.10K 가치에 해당하는 회사 주식의 0.84% 직접 소유합니다. 508.10K. 경영진과 이사회의 평균 재임 기간은 각각 4 년과 8.9 년입니다.

주요 정보

Henry Ji

최고 경영자

US$10.1m

총 보상

CEO 급여 비율	20.1%
CEO 임기	11.3yrs
CEO 소유권	0.8%
경영진 평균 재임 기간	4yrs
이사회 평균 재임 기간	8.9yrs

최근 관리 업데이트

Recent updates

Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M

Sep 29

Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

Sep 15

Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

Aug 31

Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

Aug 23

Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading

Aug 17

CEO 보상 분석

Henry Ji 의 보수는 Sorrento Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	n/a	n/a	-US$548m
Mar 31 2023	n/a	n/a	-US$672m
Dec 31 2022	US$10m	US$2m	-US$573m
Sep 30 2022	n/a	n/a	-US$494m
Jun 30 2022	n/a	n/a	-US$524m
Mar 31 2022	n/a	n/a	-US$472m
Dec 31 2021	US$20m	US$2m	-US$428m
Sep 30 2021	n/a	n/a	-US$355m
Jun 30 2021	n/a	n/a	-US$320m
Mar 31 2021	n/a	n/a	-US$231m
Dec 31 2020	US$158m	US$839k	-US$298m
Sep 30 2020	n/a	n/a	-US$290m
Jun 30 2020	n/a	n/a	-US$270m
Mar 31 2020	n/a	n/a	-US$249m
Dec 31 2019	US$8m	US$781k	-US$292m
Sep 30 2019	n/a	n/a	-US$279m
Jun 30 2019	n/a	n/a	-US$262m
Mar 31 2019	n/a	n/a	-US$279m
Dec 31 2018	US$5m	US$670k	-US$204m
Sep 30 2018	n/a	n/a	-US$105m
Jun 30 2018	n/a	n/a	-US$60m
Mar 31 2018	n/a	n/a	-US$378k
Dec 31 2017	US$2m	US$600k	US$9m

보상 대 시장: Henry 의 총 보상 ($USD 10.07M )은 US 시장( $USD 683.56K ).

보상과 수익: Henry 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Henry Ji (59 yo)

11.3yrs

테뉴어

US$10,069,893

보상

Dr. Henry H. Ji, Ph D., serves as Executive Chairman at Scilex Holding Company since September 22, 2023. He serves as Director at Aardvark Therapeutics, Inc. since 2022.Dr. Ji served as Executive Chairman...

리더십 팀

이름	위치	테뉴어	보상	소유권
Henry Ji	Chairman	11.3yrs	US$10.07m	0.84% $ 508.1k
Brian Cooley	Senior Vice President of Corporate Communications & Lymphatic Drug Development BU	2yrs	데이터 없음	데이터 없음
Michael Royal	SVP & Chief Medical Officer	4yrs	US$557.04k	데이터 없음
Alexis Nahama	Senior Vice President of Neurotherapeutics BU	4yrs	데이터 없음	데이터 없음
Mark Brunswick	Senior Vice President of Regulatory Affairs	4yrs	데이터 없음	데이터 없음
Shawn Sahebi	Senior Vice President of Commercial Operations	4yrs	데이터 없음	데이터 없음
Xiao Xu	President of ACEA	2yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

경험이 풍부한 관리: SRNE.Q 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Henry Ji	Chairman	18yrs	US$10.07m	0.84% $ 508.1k
David Lemus	Independent Director	6.3yrs	US$181.33k	0% $ 0
Jaisim Shah	Director	10.3yrs	US$868.23k	0.021% $ 12.5k
Kim Janda	Chair of Scientific Advisory Board & Director	11.8yrs	US$82.50k	0% $ 0
Yue Wu	Independent Director	7.4yrs	US$150.00k	0.00092% $ 555.2
Dorman Followwill	Lead Independent Director	6.3yrs	US$250.02k	0.00039% $ 235.4

8.9yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: SRNE.Q 의 이사회는 경험(평균 재직 기간 8.9 년)으로 간주됩니다.

Sorrento Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc., Annual General Meeting, Apr 06, 2023

Less than half of directors are independent

Less than half of directors are independent

Sorrento Therapeutics, Inc., Annual General Meeting, Dec 15, 2022

Less than half of directors are independent

Recent updates

Final DIP Financing Approved for Sorrento Therapeutics, Inc.

Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R Mzl)

Sorrento Therapeutics, Inc. Announces Full Enrollment of Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), Second Generation Oral Mpro Inhibitor, as Standalone Treatment for COVID-19

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from S&P Biotechnology Select Industry Index

Sorrento Therapeutics Received Written Notice from the Staff of The Nasdaq Stock Market LLC

Sorrento Therapeutics, Inc., Annual General Meeting, Apr 06, 2023

Sorrento Therapeutics, Inc. Releases Unblinded Phase 1B Study Data of Its Oral Main Viral Protease Inhibitor, OVYDSO™ (STI-1558) in Covid Patients

Sorrento Therapeutics Receives FDA Clearance to Initiate Clinical Trials with A Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

Sorrento Therapeutics, Inc. Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented At Asian Congress of the European Society for Medical Oncology (Esmo)

Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from A Phase IB Study in China with STI-1558

No longer forecast to breakeven

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$5.00

No longer forecast to breakeven

Less than half of directors are independent

Sorrento Therapeutics, Inc., Annual General Meeting, Dec 15, 2022

Sorrento Therapeutics, Inc. Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with Sti-1558, an Oral Mpro Inhibitor as A Standalone Oral Treatment and Prevention of Covid-19 Without the Need for A Ritonavir Booster

Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M

Sorrento Therapeutics, Inc. Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures At 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections

Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

Sorrento Therapeutics, Inc. Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer

Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

Sorrento Therapeutics, Inc. Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients

Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc. Announces the Completion of the SAD Portion of the Phase 1 Study of Its Oral Main Viral Protease (Mpro) Inhibitor, the STI-1558

Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

Sorrento Therapeutics: The Enigma

Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical

Sorrento Therapeutics, Inc. Announces First Subject Dosed in A Phase I Clinical Study of Sti-1558, an Oral Mpro Inhibitor as A Standalone Treatment and Prevention of Covid-19 Without Co-Administration of Ritonavir Booster

Less than half of directors are independent

Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

Sorrento Therapeutics, Inc. Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern

Sorrento Therapeutics, Inc. Announces That It Has Received Clearance from the FDA for Its Investigational New Drug Application for Intravenous (Iv) Sti-9167

Sorrento Therapeutics Announces the Appointment of Laura Hamill to Its Board of Directors

Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients with Severe Pneumonia Due to Covid-19

Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues

Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure

Sorrento Therapeutics, Inc. announced delayed annual 10-K filing

Sorrento Therapeutics, Inc Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) acquired an unknown majority stake in Zhengzhou Fortune Bioscience Co., Ltd..

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of Virex Health, Inc.

Sorrento Announces its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Sorrento Therapeutics, Inc. Announces Covishield (STI-9167), A Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346K) Variants of Sars-Cov-2

Sorrento Therapeutics, Inc. Announces Completion of Enrollment in US Phase 2 Clinical Trial for Covi-Drops and Achievement of Interim Analysis Threshold in the UK

Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors

Sorrento Therapeutics, Inc. Begins Enrollment in Phase 2 Trial of Resiniferatoxin for the Treatment of Pain Due to Knee Osteoarthritis (OA)

Sorrento Announces Publication of Series of Novel Sars-Cov-2 Main Protease (Mpro) Inhibitors for Potential Treatment of Covid-19 Patients Infected with Sars-Cov-2 Variants of Concern, Including Omicron

Insufficient new directors

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.33 loss in 3Q 2020)

Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates

Board Member exercised options and sold US$250k worth of stock

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

Board Member notifies of intention to sell stock

Independent Director exercised options to buy US$1.5m worth of stock.

Sorrento Therapeutics, Inc. Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients